<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01369875</url>
  </required_header>
  <id_info>
    <org_study_id>110163</org_study_id>
    <secondary_id>11-C-0163</secondary_id>
    <nct_id>NCT01369875</nct_id>
  </id_info>
  <brief_title>Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma</brief_title>
  <official_title>Phase II Study of Lymphocytes Generated With Engineered Cells for Costimulation Enhancement in Patients With Metastatic Melanoma Following Lymphodepletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor&#xD;
      tissue. The cells are modified to help them kill tumor cells, then given back to the person&#xD;
      with cancer. By giving these cells to patients, researchers hope to improve the current&#xD;
      treatments available for patients with melanoma that has not responded to standard therapies.&#xD;
      The TIL will be given after treatments that will suppress the immune system. This makes it&#xD;
      easier for the TIL to attack the cancer cells. The TIL will also be given with aldesleukin&#xD;
      (IL-2), which is designed to help keep the TIL cells alive in the body.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To study the safety and effectiveness of specially modified tumor infiltrating lymphocytes&#xD;
      to treat melanoma that has not responded to other treatments.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have metastatic melanoma that has not responded to&#xD;
      other treatments.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. They will also&#xD;
           have blood tests and imaging studies.&#xD;
&#xD;
        -  A piece of tumor will be collected and white blood cells will be separated to make the&#xD;
           TIL for the treatment.&#xD;
&#xD;
        -  Participants will take drugs to suppress the immune system for 7 days before the start&#xD;
           of treatment.&#xD;
&#xD;
        -  Participants will receive the TIL in a single dose. Then they will receive IL-2 every 8&#xD;
           hours for up to 15 doses. Participants will remain in the hospital for up to 2 weeks&#xD;
           after treatment. They will be monitored with frequent blood tests and other studies.&#xD;
&#xD;
        -  After leaving the hospital, participants will have regular followup visits every 1 to 4&#xD;
           months for the first year. Then they will return for followup every 3 to 4 months, as&#xD;
           directed by the study researchers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Tumor Infiltrating Lymphocyte (TIL) administration and high dose interleukin (IL)-2&#xD;
           following lymphodepletion can mediate durable complete responses in patients with&#xD;
           refractory melanoma. Obstacles to administration of this therapy include failure to&#xD;
           establish TIL in vitro for about 20% of patients, long delays between tumor resection&#xD;
           and TIL establishment resulting in poor TIL attributes for therapy and patient&#xD;
           ineligibility due to progression, and requirements for large numbers of feeder cells for&#xD;
           TIL expansion to therapeutic numbers.&#xD;
&#xD;
        -  The K562 cell line was engineered to express the 4-1BBL costimulatory molecule and CD64&#xD;
           (the high affinity Fc receptor for loading with antibodies such as OKT3). The&#xD;
           K562.CD64.4-1BBL Engineered Cells with Costimulation Enhancement (ECCE) replaced up to&#xD;
           75% of feeder cells in large scale TIL expansions. ECCE added to tumor cell suspensions&#xD;
           provided costimulation in trans resulting in rapid and reliable lymphocyte growth even&#xD;
           from tumors with no TIL growth under standard conditions.&#xD;
&#xD;
        -  A cloned K562.CD64.4-1BBL-7F11 ECCE line was produced under Good Manufacturing Practice&#xD;
           (GMP) conditions and a master cell bank has been generated. An optimized protocol was&#xD;
           established to rapidly expand (REP) young TIL using minimum feeders and 7F11. These ECCE&#xD;
           REPed TIL retained tumor recognition and some other attributes of standard TIL, but&#xD;
           differed from standard TIL by containing fewer CD4+ cells and more natural killer cells.&#xD;
&#xD;
      When 7F11ECCE were added directly to single cell tumor suspensions, young TIL cultures were&#xD;
      reliably generated even from patients who otherwise would not have a standard young TIL&#xD;
      culture for treatment.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
        -  In cohort 1, to evaluate whether young TIL that are rapidly expanded using 7F11 ECCE to&#xD;
           replace some feeder cells and administered with IL-2 in patients following a non&#xD;
           -myeloablative conditioning regimen will result in clinical tumor regression in patients&#xD;
           with refractory metastatic melanoma.&#xD;
&#xD;
        -  In Cohort 2, to evaluate whether young TIL generated using in trans costimulation with&#xD;
           7F11 ECCE in patients for whom standard young TIL did not grow can mediate tumor&#xD;
           regression after a nonmyeloablative conditioning with high dose IL-2 in patients with&#xD;
           refractory metastatic melanoma.&#xD;
&#xD;
        -  Determine the toxicity of ECCE young TIL in these treatment regimens&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Patients who are 18 years of age or older must have:&#xD;
&#xD;
        -  metastatic melanoma;&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
        -  One or more lesions 2 cm or greater suitable for resection for TIL culture&#xD;
&#xD;
      Patients may not have:&#xD;
&#xD;
        -  Concurrent major medical illnesses;&#xD;
&#xD;
        -  Any form of immunodeficiency;&#xD;
&#xD;
        -  Severe hypersensitivity to any of the agents used in this study;&#xD;
&#xD;
        -  Contraindications for high dose IL-2 administration.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Patients will undergo resection to obtain tumor for generation of autologous young TIL&#xD;
           cultures.&#xD;
&#xD;
        -  Parallel TIL cultures will be established using a) the standard technique with IL-2 only&#xD;
           and b) the Engineered Cells with Costimulation Enhancement (ECCE) protocol using&#xD;
           irradiated K562.CD64.4-1BBL-7F11 (7F11) cells.&#xD;
&#xD;
        -  After 10 to 20 days cultures will undergo evaluation for TIL establishment. Standard TIL&#xD;
           will be used preferentially and patients who have TIL established by standard methods&#xD;
           will be assigned to Cohort 1&#xD;
&#xD;
        -  Cohort 1:&#xD;
&#xD;
             -  TIL will undergo ECCE REP by exposure to OKT-3, IL-2, feeder cells and irradiated&#xD;
                7F11.&#xD;
&#xD;
             -  Patients will receive a non-myeloablative lymphocyte depleting preparative regimen&#xD;
                of cyclophosphamide (60 mg/kg/day intravenous (IV)) on days -7 and -6 and&#xD;
                fludarabine (25 mg/m^2/day IV) on days -5 through -1.&#xD;
&#xD;
             -  On day 0 patients will receive the infusion of autologous young TIL and then begin&#xD;
                highdose aldesleukin (720,000 IU/kg IV every 8 hours for up to 15 doses).&#xD;
&#xD;
             -  Clinical and immunologic response will be evaluated about 4-6 weeks after&#xD;
                treatment.&#xD;
&#xD;
             -  Using an optimal two-stage Phase II design, initially 18 patients will be enrolled,&#xD;
                and if three or more of the first 18 patients have a clinical response (partial&#xD;
                response (PR) or complete response (CR)), accrual will continue to 35 patients,&#xD;
                targeting a 30% goal for objective response.&#xD;
&#xD;
        -  If standard young TIL fail to grow then ECCE young TIL will be evaluated and patients&#xD;
           who have ECCE TIL available will be assigned to Cohort 2 .&#xD;
&#xD;
        -  Cohort 2:&#xD;
&#xD;
             -  Cultures from patients in Cohort 2 will be evaluated for ECCE TIL establishment. If&#xD;
                adequate ECCE TIL are available, TIL will undergo ECCE REP by exposure to OKT-3,&#xD;
                IL-2, feeder cells and irradiated 7F11.&#xD;
&#xD;
             -  Patients will receive a non-myeloablative lymphocyte depleting preparative regimen&#xD;
                of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25&#xD;
                mg/m^2/day IV) on days -5 through -1.&#xD;
&#xD;
             -  On day 0 patients will receive the infusion of autologous young TIL and then begin&#xD;
                highdose aldesleukin (720,000 IU/kg IV every 8 hours for up to 15 doses).&#xD;
&#xD;
             -  Clinical and immunologic response will be evaluated about 4-6 weeks after TIL&#xD;
                infusion.&#xD;
&#xD;
             -  Using a small optimal two-stage Phase II design, initially 9 patients will be&#xD;
                enrolled, and if one or more of the first 9 patients has a clinical response (PR or&#xD;
                CR), accrual will continue to 24 patients, targeting a 25% goal for objective&#xD;
                response.&#xD;
&#xD;
        -  If TIL cultures were not established by either standard methods or ECCE young TIL&#xD;
           protocols, patients will be eligible for re-resection and evaluation of TIL from a&#xD;
           different site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Premature closure. Protocol did not meet its primary objective.&#xD;
  </why_stopped>
  <start_date type="Actual">June 17, 2011</start_date>
  <completion_date type="Actual">February 14, 2012</completion_date>
  <primary_completion_date type="Actual">February 13, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Tumor Regression.</measure>
    <time_frame>up to approximately 8 months</time_frame>
    <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study, up to approximately 8 months.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6</description>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)</description>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)</description>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_label>Standard Young TIL</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor Infiltrating Lymphocytes</intervention_name>
    <description>Intravenous (IV) over 30 minutes on day 0</description>
    <arm_group_label>ECCE Young TIL</arm_group_label>
    <arm_group_label>Standard Young TIL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
               1. Measurable metastatic melanoma with at least one lesion that is resectable for&#xD;
                  tumor infiltrating lymphocytes (TIL) generation.&#xD;
&#xD;
               2. Patients with 3 or less brain metastases are eligible. Note: If lesions are&#xD;
                  symptomatic or greater than or equal to 1 cm each, these lesions must have been&#xD;
                  treated and stable for 3 months for the patient to be eligible.&#xD;
&#xD;
               3. Greater than or equal to 18 years of age.&#xD;
&#xD;
               4. Willing to sign a durable power of attorney&#xD;
&#xD;
               5. Able to understand and sign the Informed Consent Document&#xD;
&#xD;
               6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.&#xD;
&#xD;
               7. Life expectancy of greater than three months.&#xD;
&#xD;
               8. Patients of both genders must be willing to practice birth control from the time&#xD;
                  of enrollment on this study and for up to four months after receiving the&#xD;
                  preparative regimen.&#xD;
&#xD;
               9. Serology:&#xD;
&#xD;
                    1. Seronegative for human immunodeficiency virus (HIV) antibody. (The&#xD;
                       experimental treatment being evaluated in this protocol depends on an intact&#xD;
                       immune system. Patients engineered cells with costimulation enhancement&#xD;
                       (ECCE) TIL 14 who are HIV seropositive can have decreased immune-competence&#xD;
                       and thus be less responsive to the experimental treatment and more&#xD;
                       susceptible to its toxicities.)&#xD;
&#xD;
                    2. Seronegative for hepatitis B antigen, and seronegative for hepatitis C&#xD;
                       antibody. If hepatitis C antibody test is positive, then patient must be&#xD;
                       tested for the presence of antigen by reverse transcription polymerase chain&#xD;
                       reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA)&#xD;
                       negative.&#xD;
&#xD;
                    3. Women of child-bearing potential must have a negative pregnancy test because&#xD;
                       of the potentially dangerous effects of the preparative chemotherapy on the&#xD;
                       fetus.&#xD;
&#xD;
              10. Hematology:&#xD;
&#xD;
                    1. Absolute neutrophil count greater than 1000/mm^3 without the support of&#xD;
                       filgrastim.&#xD;
&#xD;
                    2. White blood cell (WBC) (&gt; 3000/mm^3).&#xD;
&#xD;
                    3. Platelet count greater than 100,000/mm^3.&#xD;
&#xD;
                    4. Hemoglobin greater than 8.0 g/dl.&#xD;
&#xD;
              11. Chemistry:&#xD;
&#xD;
                    1. Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less&#xD;
                       or equal to 2.5 times the upper limit of normal.&#xD;
&#xD;
                    2. Serum creatinine less than or equal to 1.6 mg/dl.&#xD;
&#xD;
                    3. Total bilirubin less than or equal to 1.5 mg/dl, except in patients with&#xD;
                       Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.&#xD;
&#xD;
              12. More than four weeks must have elapsed since any prior systemic therapy at the&#xD;
                  time the patient receives the preparative regimen, and patients' toxicities must&#xD;
                  have recovered to a grade 1 or less (except for toxicities such as alopecia or&#xD;
                  vitiligo). Patients may have undergone minor surgical procedures within the past&#xD;
                  3 weeks, as long as all toxicities have recovered to grade 1 or less.&#xD;
&#xD;
              13. Six weeks must have elapsed since any prior anti-cytotoxic T-lymphocyte antigen 4&#xD;
                  (CTLA4) antibody therapy to allow antibody levels to decline.&#xD;
&#xD;
              14. Patients who have previously received any anti-CTLA4 antibody and have documented&#xD;
                  gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic&#xD;
                  biopsies.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Women of child-bearing potential who are pregnant or breastfeeding because of the&#xD;
             potentially dangerous effects of the preparative chemotherapy on the fetus or infant.&#xD;
&#xD;
          2. Systemic steroid therapy required.&#xD;
&#xD;
          3. Active systemic infections, coagulation disorders or other major medical illnesses of&#xD;
             the cardiovascular, respiratory or immune system, myocardial infarction, cardiac&#xD;
             arrhythmias, obstructive or restrictive pulmonary disease.&#xD;
&#xD;
          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency&#xD;
             Disease).&#xD;
&#xD;
          5. Concurrent opportunistic infections (The experimental treatment being evaluated in&#xD;
             this protocol depends on an intact immune system. Patients who ECCE TIL 15 have&#xD;
             decreased immune competence may be less responsive to the experimental treatment and&#xD;
             more susceptible to its toxicities).&#xD;
&#xD;
          6. History of severe immediate hypersensitivity reaction to any of the agents used in&#xD;
             this study.&#xD;
&#xD;
          7. History of coronary revascularization or ischemic symptoms&#xD;
&#xD;
          8. Any patient known to have an left ventricular ejection fraction (LVEF) less than or&#xD;
             equal to 45%.&#xD;
&#xD;
          9. Documented LVEF of less than or equal to 45% tested in patients with:&#xD;
&#xD;
               -  Clinically significant atrial and/or ventricular arrhythmias including but not&#xD;
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree&#xD;
                  heart block&#xD;
&#xD;
               -  Age greater than or equal to 60 years old&#xD;
&#xD;
         10. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted&#xD;
             tested in patients with:&#xD;
&#xD;
               -  A prolonged history of cigarette smoking&#xD;
&#xD;
               -  Symptoms of respiratory dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A Rosenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0163.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66.</citation>
    <PMID>17237035</PMID>
  </reference>
  <reference>
    <citation>Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105-16. Review.</citation>
    <PMID>10561265</PMID>
  </reference>
  <reference>
    <citation>Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer. 2007 Feb 1;109(3):455-64. Review.</citation>
    <PMID>17200963</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>February 14, 2013</results_first_submitted>
  <results_first_submitted_qc>February 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2013</results_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Steven Rosenberg, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>Skin Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 2, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01369875/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT01369875/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="P2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="B2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0"/>
                    <measurement group_id="B2" value="46.0"/>
                    <measurement group_id="B3" value="48.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Tumor Regression.</title>
        <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
        <time_frame>up to approximately 8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
          <group group_id="O2">
            <title>ECCE Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Tumor Regression.</title>
          <description>Clinical tumor regression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) is a disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progression (PD) is at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, up to approximately 8 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
          <group group_id="O2">
            <title>ECCE Young TIL</title>
            <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, up to approximately 8 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
        <group group_id="E2">
          <title>ECCE Young TIL</title>
          <description>Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0&#xD;
Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)&#xD;
Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)&#xD;
Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>fever of unknown origin without clinically or microbiologically documented infection) (ANC &lt;1.0 x 10e9/L, fever &gt;=38.5 degrees C)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: motor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Rosenberg</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-4164</phone>
      <email>sar@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

